Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.

@article{Saif2013Bolus5A,
  title={Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.},
  author={Muhammad Wasif Saif and Marie Carmel Garcon and Gladys Soto Rodr{\'i}guez and Teresa Rodr{\'i}guez},
  journal={In vivo},
  year={2013},
  volume={27 4},
  pages={531-4}
}
BACKGROUND 5-Fluorouracil (5-FU) is the backbone of chemotherapy regimens approved for treatment of colorectal cancer. The incidence of cardiotoxicity associated with 5-FU ranges from 1.5% to 18%; 48% as anginal symptoms and 2% as cardiogenic shock. Cardiotoxicity is unpredictable and no alternative chemotherapeutics have been defined so far. PATIENTS AND… CONTINUE READING